These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25384088)

  • 1. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
    Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
    J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
    Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T
    Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
    Suzuki K; Harada A; Shiraishi E; Kimura H
    J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.
    Harada A; Suzuki K; Kamiguchi N; Miyamoto M; Tohyama K; Nakashima K; Taniguchi T; Kimura H
    PLoS One; 2015; 10(3):e0122197. PubMed ID: 25815469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing phototoxicity observed in a novel series of biaryl derivatives: discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436.
    Hamaguchi W; Masuda N; Miyamoto S; Kikuchi S; Narazaki F; Shiina Y; Seo R; Amano Y; Mihara T; Moriguchi H; Hattori K
    Bioorg Med Chem; 2015 Jul; 23(13):3351-67. PubMed ID: 25960322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.
    Yoshikawa M; Hitaka T; Hasui T; Fushimi M; Kunitomo J; Kokubo H; Oki H; Nakashima K; Taniguchi T
    Bioorg Med Chem; 2016 Aug; 24(16):3447-55. PubMed ID: 27301679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
    Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
    J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
    Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
    J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
    Mikami S; Nakamura S; Ashizawa T; Nomura I; Kawasaki M; Sasaki S; Oki H; Kokubo H; Hoffman ID; Zou H; Uchiyama N; Nakashima K; Kamiguchi N; Imada H; Suzuki N; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7677-7702. PubMed ID: 28796496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition.
    Hamaguchi W; Masuda N; Miyamoto S; Shiina Y; Kikuchi S; Mihara T; Moriguchi H; Fushiki H; Murakami Y; Amano Y; Honbou K; Hattori K
    Bioorg Med Chem; 2015 Jan; 23(2):297-313. PubMed ID: 25515954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
    Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
    J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
    Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
    Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.
    Suzuki K; Harada A; Suzuki H; Capuani C; Ugolini A; Corsi M; Kimura H
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
    Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
    J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
    Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
    Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
    Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
    J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and in vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors.
    Hamaguchi W; Masuda N; Samizu K; Mihara T; Takama K; Watanabe T
    Chem Pharm Bull (Tokyo); 2014; 62(12):1200-13. PubMed ID: 25450629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
    Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
    Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A.
    Burdi DF; Campbell JE; Wang J; Zhao S; Zhong H; Wei J; Campbell U; Shao L; Herman L; Koch P; Jones PG; Hewitt MC
    Bioorg Med Chem Lett; 2015 May; 25(9):1864-8. PubMed ID: 25863433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.